CXorf51A
gene geneOn this page
Summary
CXorf51A (chromosome X open reading frame 51A, HGNC:30533) is a protein-coding gene on chromosome Xq27.3, encoding Uncharacterized protein CXorf51A (A0A1B0GTR3).
At a glance
- Clinical variants (ClinVar): 4 total — 1 likely-pathogenic
- MANE Select transcript:
NM_001144064
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:30533 |
| Approved symbol | CXorf51A |
| Name | chromosome X open reading frame 51A |
| Location | Xq27.3 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000224440 |
| Ensembl biotype | protein_coding |
| Entrez | 100129239 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000458472
RefSeq mRNA: 1 — MANE Select: NM_001144064
NM_001144064
CCDS: CCDS83498
Canonical transcript exons
ENST00000458472 — 2 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001620703 | 146814106 | 146814401 |
| ENSE00001633368 | 146814592 | 146814744 |
Expression profiles
Bgee: expression breadth broad, 30 present calls, max score 94.52.
Top tissues by expression
93 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 94.52 | gold quality |
| left testis | UBERON:0004533 | 52.29 | gold quality |
| testis | UBERON:0000473 | 50.82 | gold quality |
| right testis | UBERON:0004534 | 49.21 | gold quality |
| colonic epithelium | UBERON:0000397 | 37.20 | gold quality |
| ventricular zone | UBERON:0003053 | 36.48 | gold quality |
| cortical plate | UBERON:0005343 | 36.47 | gold quality |
| bone marrow cell | CL:0002092 | 36.16 | gold quality |
| ganglionic eminence | UBERON:0004023 | 35.49 | gold quality |
| right coronary artery | UBERON:0001625 | 35.15 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 33.38 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 32.15 | gold quality |
| bone marrow | UBERON:0002371 | 31.74 | gold quality |
| muscle tissue | UBERON:0002385 | 31.06 | gold quality |
| sural nerve | UBERON:0015488 | 30.93 | gold quality |
| stromal cell of endometrium | CL:0002255 | 29.87 | gold quality |
| prefrontal cortex | UBERON:0000451 | 29.59 | silver quality |
| duodenum | UBERON:0002114 | 28.14 | gold quality |
| muscle of leg | UBERON:0001383 | 27.76 | gold quality |
| lymph node | UBERON:0000029 | 27.57 | gold quality |
| gastrocnemius | UBERON:0001388 | 27.18 | gold quality |
| tonsil | UBERON:0002372 | 27.05 | gold quality |
| islet of Langerhans | UBERON:0000006 | 26.55 | gold quality |
| vermiform appendix | UBERON:0001154 | 26.42 | gold quality |
| blood | UBERON:0000178 | 26.11 | gold quality |
| gall bladder | UBERON:0002110 | 25.98 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 25.89 | gold quality |
| placenta | UBERON:0001987 | 25.81 | gold quality |
| leukocyte | CL:0000738 | 25.71 | gold quality |
| monocyte | CL:0000576 | 25.52 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 0.00 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
8 targeting CXorf51A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-552-5P | 99.93 | 68.56 | 1583 |
| HSA-MIR-4420 | 99.82 | 70.08 | 1624 |
| HSA-MIR-181B-2-3P | 99.81 | 70.06 | 1646 |
| HSA-MIR-181B-3P | 99.81 | 70.06 | 1646 |
| HSA-MIR-11399 | 98.71 | 65.69 | 869 |
| HSA-MIR-653-3P | 98.31 | 67.71 | 1542 |
| HSA-MIR-649 | 97.96 | 67.21 | 704 |
| HSA-MIR-490-3P | 97.79 | 65.54 | 606 |
Literature-anchored findings (GeneRIF, showing 1)
- Backbone and nearly complete side-chain chemical shift assignments reveal the human uncharacterized protein CXorf51A as intrinsically disordered. (PMID:34415548)
Cross-species orthologs
0 orthologs
Paralogs (1): CXorf51B (ENSG00000235699)
Protein
Protein identifiers
Uncharacterized protein CXorf51A — A0A1B0GTR3 (reviewed: A0A1B0GTR3)
All UniProt accessions (1): A0A1B0GTR3
RefSeq proteins (1): NP_001137536* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR040433 | Spermatid_TP | Family |
UniProt features (6 total): compositionally biased region 4, chain 1, region of interest 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-A0A1B0GTR3-F1 | 69.50 | 0.02 |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 7 (showing top):
chrXq27, GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_72H_ACT_CD4_TCELL_UP, GSE21546_UNSTIM_VS_ANTI_CD3_STIM_SAP1A_KO_AND_ELK1_KO_DP_THYMOCYTES_UP, GSE41867_NAIVE_VS_DAY15_LCMV_CONE13_EFFECTOR_CD8_TCELL_UP, GSE41867_DAY6_VS_DAY15_LCMV_CLONE13_EFFECTOR_CD8_TCELL_UP, GSE46242_CTRL_VS_EGR2_DELETED_TH1_CD4_TCELL_DN, GSE46606_DAY1_VS_DAY3_CD40L_IL2_IL5_STIMULATED_BCELL_UP
GO Biological Process (0):
GO Molecular Function (0):
GO Cellular Component (0):
Protein interactions and networks
STRING
114 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| CXorf51A | CXorf49 | A8MYA2 | 691 |
| CXorf51A | OFD1 | O75665 | 670 |
| CXorf51A | EOLA2 | Q96DE9 | 646 |
| CXorf51A | PWWP4 | A0A494C071 | 643 |
| CXorf51A | FMR1NB | Q8N0W7 | 582 |
| CXorf51A | TCP11X2 | Q5H9J9 | 571 |
| CXorf51A | SPANXN4 | Q5MJ08 | 571 |
| CXorf51A | SPANXN3 | Q5MJ09 | 545 |
| CXorf51A | EOLA1 | Q8TE69 | 513 |
| CXorf51A | SPANXN2 | Q5MJ10 | 511 |
| CXorf51A | SLITRK2 | Q9H156 | 507 |
| CXorf51A | SPANXN1 | Q5VSR9 | 507 |
| CXorf51A | HSFX4 | A0A1B0GTS1 | 506 |
| CXorf51A | SPANXA1 | Q9NS26 | 505 |
| CXorf51A | IFT172 | Q9UG01 | 491 |
IntAct
0 interactions, top by confidence:
ESM2 similar proteins: A0A1B0GTR3, A0A7H0DN82, A7RR34, E9PVX6, O14598, O60356, O60829, O94243, P04605, P04614, P05909, P0C1K0, P0C765, P0C766, P0DPH9, P17285, P17759, P18098, P19416, P20290, P24109, P46012, P46583, Q06428, Q07555, Q08561, Q09821, Q1L9C7, Q32PF3, Q3KP22, Q5M948, Q5M951, Q5MJ08, Q5RCI9, Q6P8I4, Q758T8, Q76632, Q7M2N1, Q7TP40, Q80WR5
Diamond homologs: A0A1B0GTR3, P0DPH9
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
4 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 1 |
| Uncertain significance | 2 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (1)
| Variant ID | HGVS | Classification |
|---|---|---|
| 3062552 | GRCh37/hg19 Xq27.3-28(chrX:144487227-148811395) | Likely pathogenic |
SpliceAI
0 predictions. Top by Δscore:
AlphaMissense
688 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| X:146814393:C:A | K47N | 0.689 |
| X:146814393:C:G | K47N | 0.689 |
| X:146814309:C:A | K75N | 0.680 |
| X:146814309:C:G | K75N | 0.680 |
| X:146814375:T:A | K53N | 0.664 |
| X:146814375:T:G | K53N | 0.664 |
| X:146814592:C:A | K44N | 0.644 |
| X:146814592:C:G | K44N | 0.644 |
| X:146814256:A:G | M93T | 0.580 |
dbSNP variants (sampled 9 via entrez): RS1028509 (X:146814750 C>G), RS1033644 (X:146816015 G>A), RS112574046 (X:146814621 G>A), RS1557052279 (X:146814405 C>T), RS1557052280 (X:146814597 C>T), RS1557052281 (X:146814771 A>G), RS2064681 (X:146815742 A>G), RS6626168 (X:146816270 G>T), RS6626738 (X:146815974 C>T)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
4 total (human), top 4 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| butyraldehyde | increases expression | 1 |
| Acetaminophen | decreases expression | 1 |
| Methotrexate | increases expression | 1 |
| Antirheumatic Agents | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.